Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma - Schadendorf, D; Amonkar, M M; Stroyakovskiy, D (Eur J Cancer, 2015)
, et al.